MBX Biosciences Q2 net loss $19.4M; cash $224.9M; canvuparatide Phase 2 data on track for Q3 2025

MBX Biosciences, Inc.

2025-Q2 EPS reported -$1.30

Net loss $19.4M for Q2 2025 vs $15.9M in Q2 2024; R&D expenses increased to $17.7M.
Cash, equivalents and marketable securities $224.9M as of June 30, 2025; expected to fund operations into mid-2027.
Phase 2 Avail trial of canvuparatide in hypoparathyroidism topline results expected in Q3 2025.
Phase 2a trial of imapextide (post-bariatric hypoglycemia) and Phase 1 trial of MBX 4291 (obesity) to initiate in Q3 2025.
Appointed Dr. Andreas Moraitis as SVP of Clinical Development in June 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.